







TABLE II
Additional Benzimidazoles



	R ²	R ³	Method	Recrystall solvent	Mp, °C	Yield, %	Formula	Analyses
21		H		H ₂ O	253–254 ^a	84	C ₁₅ H ₁₆ N ₂ O ₂ ·HCl	N, Cl
22		H	C	50% EtOH	184–185 ^b	34	C ₁₇ H ₂₄ N ₂ O·2C ₄ H ₁₀ O ₂	C, H, N
23		NO ₂	C	EtOH	212–214	57	C ₁₇ H ₁₈ N ₂ O ₃	C, H
24		Cl	C	EtOH	240.5–241.5	56	C ₁₆ H ₇ Cl ₃ N ₂	Cl
25		Cl	C	Xylene	226.5–227.5	28	C ₁₀ H ₇ ClN ₂ S	Cl, S

^a HCl salt: Cl calcd, 13.49; found 12.86. ^b Tartaric acid salt.

Br₂ in CCl₄ was added slowly with stirring at room temperature. The hydrobromide of the brominated product separated from the reaction mixture. The location of the Br substituent was verified by nmr spectroscopy.

Method C.—Equimolar amounts of the *o*-phenylenediamine and aromatic aldehyde were heated in PhNO₂ in a distillation apparatus until the distillate came over clear (H₂O no longer forming, usually about 30 min). The residual distilland was cooled, and the product was collected and recrystallized.

Compound 21 was prepared by refluxing a solution of 4-(2-benzimidazolyl)guaiacol⁴ in pyridine·HCl for 45 min, then pouring over ice and collecting the product. It was recrystallized from H₂O containing small amounts of NaHSO₃ and HCl.

Acknowledgments.—The author thanks Drs. A. Steyermark and F. Scheidl for microanalyses, Mr. S. Traiman for ir spectra and Dr. T. Williams for nmr spectra and interpretation.

Antitumor Activities of Some Schiff Bases

ERNEST M. HODNETT AND PAUL D. MOONEY







Department of Chemistry, Oklahoma State University,
Stillwater, Oklahoma 74074

Received January 14, 1970

Schiff bases are known to slow the growth of some animal tumors.¹ More compounds of this type have now been prepared and have been screened by the Cancer Chemotherapy National Service Center. None of these compounds showed activity against lymphoid leukemia L1210 in the mouse, but some slowed the growth of intramuscular Walker sarcoma in the rat² as shown in Table I.

(1) E. M. Hodnett and W. Willie, *Proc. Okla. Acad. Sci.*, **46**, 107 (1966).
(2) "Protocols for Screening Chemical Agents and Natural Products against Animal Tumors and Other Biological Systems," Cancer Chemotherapy National Service Center (CCNSC), *Cancer Chemother. Rept.*, **25**, 1 (1962), and as modified (Jan 1966).

TABLE I
SCHIFF BASES PREPARED
R¹CH=NR²

R ¹	R ²	Intramuscular Walker sarcoma of the rat ^a	Dose, mg/kg	<i>T</i> / <i>C</i> ^b	Ref
C ₆ H ₄ -2-OH			400	0.83	<i>c</i>
	C ₆ H ₄ -4-OH		400	1.03	<i>d</i>
	C ₆ H ₃ -2-OH-5-NO ₂		400	0.94	<i>c</i>
	C ₆ H ₅		400	0.89	<i>f</i>
	C ₆ H ₄ -2-OH		400	0.78	<i>f</i>
	C ₆ H ₄ -4-OH		400	0.58	<i>f</i>

^a The screening data were supplied through the kindness of Dr. Harry B. Wood, Jr., of the Cancer Chemotherapy National Service Center, National Institutes of Health, Bethesda, Md. Assays were performed according to CCNSC specifications as reported in ref 2. ^b Effectiveness against intramuscular Walker sarcoma of the rat is measured by weights of tumors of treated rats (*T*) compared to the tumors of control rats (*C*): the value of *T*/*C* must be 0.53 or less for significant activity. ^c Mp 77–78°. *Anal.* (C₁₀H₉N₂OS) C, H, N. ^d G. N. Walker and M. A. Klett, *J. Med. Chem.*, **9**, 624 (1966). ^e Mp 195–196°. *Anal.* (C₁₂H₉N₂O₃) C, H, N. ^f I. A. Savich, V. V. Zelentsov, and I. Spitsyn, *Vestnik Moskov Univ. Ser. Mat. Mekh., Astron., Fiz., Khim.*, **11**, 233 (1956); *Chem. Abst.*, **53**, 1264h (1959).

Acknowledgments.—Grateful acknowledgment is made of the valuable assistance of Joyce Wan, Darwin Darr, and the staff of the Research Foundation of Oklahoma State University in the preparation of these compounds and of this report.